Kathryn E. Beckermann, MD, PhD

Kathryn E. Beckermann, MD, PhD, is an assistant professor in the Department of Medicine of the Division of Hematology and Oncology at the Vanderbilt School of Medicine in Nashville, Tennessee.

Articles

Treatment Approaches for Patients with RCC and Bone Metastases

March 31st 2023

Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.

Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

March 31st 2023

The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.

Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

March 23rd 2023

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

March 23rd 2023

Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.

Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

March 15th 2023

Mehmet Asim Bilen, MD, presents a profile of a 65-year-old woman with metastatic renal cell carcinoma for discussion.

Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

March 15th 2023

Moshe Ornstein, MD, MA, starts a conversation on how patients with metastatic renal cell carcinoma are classified by risk, and how risk category influences approaches to systemic therapy.

Dr. Beckermann on the Evolving Adjuvant Setting in RCC

August 22nd 2022

Kathryn E. Beckermann, MD, PhD, discusses the evolving adjuvant treatment setting for renal cell carcinoma.

Dr. Beckermann on the Future of Treatment in RCC

August 16th 2022

Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.

Dr. Beckermann on the Need for Biomarkers in Frontline RCC

August 10th 2022

Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.

Dr. Beckermann on Investigational Treatment Strategies in mRCC

February 4th 2020

Kathryn E. Beckermann, MD, PhD, discusses investigational treatment strategies in metastatic renal cell carcinoma.

Dr. Beckermann on Sequencing Strategies in mRCC

December 4th 2019

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

Dr. Beckermann on TKI/Immunotherapy Combinations in mRCC

November 28th 2019

Kathryn E. Beckermann, MD, PhD, discusses treatment selection in metastatic renal cell carcinoma.

Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer

May 15th 2018

The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.